Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2022 16:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
November 28, 2022 07:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 14, 2022 07:01 ET
|
Viridian Therapeutics, Inc
- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 20 mg/kg VRDN-001; generally consistent with 10mg/kg results at week 6 - - Global Phase 3 THRIVE...
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
November 14, 2022 06:59 ET
|
Viridian Therapeutics, Inc
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 20 mg/kg VRDN-001, generally consistent with 10 mg/kg results at week 6 - - Global Phase 3 THRIVE clinical...
Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
November 08, 2022 07:05 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
November 08, 2022 07:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
October 22, 2022 14:04 ET
|
Viridian Therapeutics, Inc
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation - - Full 10 mg/kg cohort data presented at ATA,...
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
October 12, 2022 08:12 ET
|
Viridian Therapeutics, Inc
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept data from ongoing Phase 1/2 trial in Thyroid Eye...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering
August 25, 2022 16:03 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...